Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone

Bibliographic Details
Main Authors:	Edwards, C, Fisher, D, van Staa, T, Cooper, C, Arden, N
Format:	Conference item
Published:	2008

Similar Items

Individual DMARDs have different effects on the likelihood of developing septic arthritis in adults with rheumatoid arthritis
by: Edwards, C, et al.
Published: (2005)

Myocardial infarction in rheumatoid arthritis: The effects of traditional risk factors, anti-hypertensive and lipid-lowering medication
by: Edwards, C, et al.
Published: (2008)

The increased risk of myocardial infarction in patients with rheumatoid arthritis is greatest in young women and is not due to traditional risk factors
by: Arden, N, et al.
Published: (2006)

The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
by: Edwards, C, et al.
Published: (2007)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Biomarkers to Predict DMARDs Efficacy and Adverse Effect in Rheumatoid Arthritis
by: Kai Wei, et al.
Published: (2022-03-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Fibrinolytic activity in rheumatoid arthritis and the effects of prednisolone therapy
by: Gough, S, et al.
Published: (1993)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
by: M. J. H. Voshaar, et al.
Published: (2022-01-01)

The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database.
by: Edwards, C, et al.
Published: (2005)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
by: Jobanputra, P, et al.
Published: (2004)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

REGIONAL DIFFERENCES IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
by: Edwards, C, et al.
Published: (2012)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
by: Maria Sergeevna Voronina, et al.
Published: (2012-10-01)

ACUTE MYOCARDIAL INFARCTION IN RHEUMATOID ARTHRITIS
by: I. B. Vinogradova, et al.
Published: (2000-02-01)

Common Transcriptomic Effects of Abatacept and Other DMARDs on Rheumatoid Arthritis Synovial Tissue
by: Clement Triaille, et al.
Published: (2021-08-01)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
by: Juthamas Prawjaeng, et al.
Published: (2023-05-01)

Regional and temporal variation in the treatment of rheumatoid arthritis across the UK: a descriptive register-based cohort study
by: Edwards, C, et al.
Published: (2012)

TEMPORAL TRENDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN THE UK WITH REFERENCE TO BEST PRACTICE
by: Edwards, C, et al.
Published: (2012)

Comparative effectiveness of tumour necrosis factor inhibitor therapy vs. conventional synthetic dmards on need for joint replacement among rheumatoid arthritis patients: A propensity score matched analysis of UK registry data
by: Hawley, S, et al.
Published: (2018)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
by: James Cheng-Chung Wei, et al.
Published: (2023-07-01)

Identification of biomarkers in patients with rheumatoid arthritis responsive to DMARDs but with progressive bone erosion
by: Emiliano Marasco, et al.
Published: (2023-09-01)

Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
by: Hazan Karadeniz, et al.
Published: (2022-04-01)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
by: T. Martijn Kuijper, et al.
Published: (2017-04-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
by: Soo-Kyung Cho, et al.
Published: (2017-12-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
by: Basiru Ahmad Zago, et al.
Published: (2020-12-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study
by: Seogsong Jeong, et al.
Published: (2022-07-01)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
by: Carl K Edwards, et al.
Published: (2012-12-01)

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
by: Jin-Won Kwon, et al.
Published: (2024-04-01)

Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs
by: Kei Ikeda, et al.
Published: (2024-02-01)

Blood pro-resolving mediators are linked with synovial pathology and are predictive of DMARD responsiveness in rheumatoid arthritis
by: Esteban A. Gomez, et al.
Published: (2020-10-01)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
by: Merete Lund Hetland, et al.
Published: (2022-12-01)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
by: Judge, AD, et al.
Published: (2017)

Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis
by: C. A. Lechtenboehmer, et al.
Published: (2021-10-01)

The effect of TNF blockade on insulin resistance in patients with rheumatoid arthritis
by: Edwards, C, et al.
Published: (2006)

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01)

Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
by: Maria Kalweit, et al.
Published: (2023-06-01)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
by: Giovanni Adami, et al.
Published: (2023-01-01)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
by: Maria Chiara Gerardi, et al.
Published: (2022-08-01)